Observation Study on the Efficacy of Yiqi Gubiao Pill in the Treatment of Chronic Obstructive Pulmonary Disease Secondary to Active Pulmonary Tuberculosis

Launched by FOURTH AFFILIATED HOSPITAL OF XINJIANG MEDICAL UNIVERSITY · Nov 5, 2024

Keywords

ClinConnect Summary

This clinical trial is studying a treatment called Yiqi Gubiao Pill for patients with a type of lung disease known as tuberculosis-related obstructive pulmonary disease (TOPD). This condition happens when tuberculosis affects the lungs and makes it hard for patients to breathe. The goal of the study is to see how well the Yiqi Gubiao Pill can help improve patients' breathing and overall quality of life, while also checking how safe the pill is to use.

To participate in this study, individuals need to be between 40 and 75 years old and diagnosed with active pulmonary tuberculosis. They should not have taken certain medications like steroids or other treatments that could affect their immune system in the past month. Participants will be randomly assigned to either receive the Yiqi Gubiao Pill or a placebo (a pill that looks the same but has no active ingredients) for 12 weeks. Throughout this period, researchers will monitor their lung function and how they feel overall. The study is not yet recruiting, but it aims to gather important information to help manage this serious lung condition better.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • -
• Patients who meet the following criteria will be included:
• • 1. Age 40-75 years old;
• • 2. Meet the Western medical diagnostic criteria and typing standards for active PTB;
• • 3. Patients who have not taken steroids, anti-tuberculosis drugs, or other immunosuppressants and have not undergone desensitization treatment within one month.
• • 4. Have understood the treatment methods and voluntarily signed the informed consent form.
• Exclusion Criteria:
• • -
• Patients who meet any of the following criteria will be excluded:
• • 1. Patients with pneumothorax, pleural effusion, lung cancer and other serious lung diseases;
• • 2. Patients with severe cardiovascular and cerebrovascular, hepatorenal and hematopoietic diseases;
• • 3. mentally ill;
• • 4. Patients with tumors;
• • 5. Congenital or acquired immunodeficiency.